Prescient Therapeutics Limited (ASX:PTX)
Australia · Delayed Price · Currency is AUD 0.0670
+0.0020 (3.08%)
Sep 11, 2026, 11:34 AM AEST
Prescient Therapeutics Revenue
In the fiscal year ending June 30, 2026, Prescient Therapeutics had annual revenue of 3.45M AUD, down -20.78%. Prescient Therapeutics had revenue of 2.29M in the half year ending June 30, 2026, with 29.38% growth.
Revenue
3.45M
Revenue Growth
-20.78%
P/S Ratio
19.80
Revenue / Employee
1.15M
Employees
3
Market Cap
68.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.45M | -905.30K | -20.78% |
| Jun 30, 2025 | 4.36M | 644.03K | 17.35% |
| Jun 30, 2024 | 3.71M | 1.28M | 52.89% |
| Jun 30, 2023 | 2.43M | 538.79K | 28.52% |
| Jun 30, 2022 | 1.89M | 703.86K | 59.37% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 33.80M |
| Immutep | 19.93M |
| Neurizon Therapeutics | 17.59M |
| Radiopharm Theranostics | 13.50M |
| Recce Pharmaceuticals | 9.47M |
| Amplia Therapeutics | 4.79M |
| Alterity Therapeutics | 3.61M |
| Arovella Therapeutics | 3.50M |